Literature DB >> 21573990

Ivabradine added to guidelines-based therapy in systolic heart failure patients.

Anna Maria Rusconi1, Elisa Ceriani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21573990     DOI： 10.1007/s11739-011-0594-7

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  6 in total

1.  Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.

Authors:  Ariel Diaz; Martial G Bourassa; Marie-Claude Guertin; Jean-Claude Tardif
Journal:  Eur Heart J       Date:  2005-03-17       Impact factor: 29.983

2.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

3.  Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.

Authors:  Jeffrey S Borer; Kim Fox; Patrice Jaillon; Guy Lerebours
Journal:  Circulation       Date:  2003-02-18       Impact factor: 29.690

4.  Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice.

Authors:  Giorgio Costantino; Anna Maria Rusconi; Pier Giorgio Duca; Stefano Guzzetti; Ilaria Bossi; Marta Del Medico; Giuseppina Pisano; Mara Bulgheroni; Monica Solbiati; Raffaello Furlan; Nicola Montano
Journal:  Intern Emerg Med       Date:  2008-08-09       Impact factor: 3.397

5.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

6.  Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.

Authors:  Jean-Claude Tardif; Piotr Ponikowski; Thomas Kahan
Journal:  Eur Heart J       Date:  2009-01-09       Impact factor: 29.983
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.